ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

GLP1-RAs, SGLT2i Are Underutilized in Kidney Transplant Recipients with Diabetes Mellitus and Obesity

M. Stumpf, S. A. Dar, S. Rao, A. Doyle

University of Virginia, Charlottesville, VA

Meeting: 2020 American Transplant Congress

Abstract number: A-062

Keywords: Hyperglycemia, Kidney transplantation, Metabolic complications, Post-transplant diabetes

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session A: Kidney: Cardiovascular and Metabolic Complications

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • Serum Apolipoproteins B and A1 Predict the Development of Late Post-Transplant Diabetes Mellitus in Prevalent Adult Kidney Transplant Recipients
  • Diabetes Mellitus Predicts Outcome in Obesity After Kidney Transplantation.

*Purpose: There is little research describing differences in use of antidiabetic medications amongst obese, diabetic patients with or without a history of kidney transplant. More specifically, commonly used oral antidiabetic drugs (OADs) like metformin, GLP1-RA, and SGLT2i have favorable effects on glycemic control and weight loss . We sought to determine the odds ratio of use of OADs amongst obese, diabetic patients with or without a history of kidney transplant.

*Methods: This study was cross-sectional in design. A de-identified database was utilized to query for patients (>18yo) seen at a single tertiary medical center with diagnosis code of diabetes mellitus (DM) and either a diagnosis code of obesity or BMI >30 kg/m2 (Cases) vs no obesity (Control). The same query was then conducted to include only patients with diagnosis code of kidney transplant (Table 1). No exclusions were made based on kidney function. Given obesity, an Odds Ratio (OR) was then calculated for use of OADs in both patients with history of kidney transplant and those without (OR = [cases exposed to drug/cases unexposed to drug]/[controls exposed to drug/controls unexposed]).

*Results: ORs were calculated and presented in Figure 1. Metformin use was not significantly different between the two groups (OR without kidney transplant was 1.57 [95%CI 1.48-1.67], OR with transplant was 1.22 [95%CI 0.88-1.68]). However, SGLT2i and GLP1-RA therapy were both significantly less likely to be used in patients who have kidney transplant history. OR of SGLT2i without transplant 1.86 [95%CI 1.48-2.5] vs OR of SGLT2i in transplant 0.69 [95%CI 0.41-1.18]. OR of GLP1-RA without transplant 3.61 [95%CI 2.97-4.39] vs GLP1-RA in transplant 1.29 [95%CI 0.85-1.95].

*Conclusions: Recent advances in therapy for DM include medications which favor weight loss and lend cardiovascular benefit, including GLP1-RA and SGLT2i. These medications are not contraindicated in patients with history of kidney transplant, yet are often not utilized. Further studies are needed to demonstrate safety and efficacy of these agents in patients with diabetes mellitus, obesity, and history of kidney transplant.

 border=

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Stumpf M, Dar SA, Rao S, Doyle A. GLP1-RAs, SGLT2i Are Underutilized in Kidney Transplant Recipients with Diabetes Mellitus and Obesity [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/glp1-ras-sglt2i-are-underutilized-in-kidney-transplant-recipients-with-diabetes-mellitus-and-obesity/. Accessed March 3, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.